Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $1330

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00

Wells Fargo analyst Mohit Bansal maintains Eli Lilly (NYSE: LLY) with a Overweight and raises the price target from $1280 to $1330.